October 30, 2019
The Pharmaceuticals and Medical Devices Agency (PMDA) is looking into the risk of interstitial lung disease (ILD) for prostate cancer drugs Erleada (apalutamide) and Xtandi (enzalutamide), a move likely to trigger a label change in the near future. The ongoing...read more